New positive coverage policy further validates acceptance of iFuse as an important treatment option for patients with chronic sacroiliac joint dysfunction
The new policy covers minimally invasive arthrodesis of the sacroiliac joint (e.g., iFuse) for sacroiliac joint syndrome and sacroiliac joint pain. This decision was based upon the extensive amount of published clinical evidence demonstrating the safety and effectiveness of the iFuse Implant System, including recently published 5-year results from a long-term prospective study called LOIS (Long Term Outcomes from INSITE and SIFI).
Aetna is the third largest commercial health plan in
“As a result of this positive coverage decision, Aetna’s 22 million medical plan members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
Source: SI-BONE, Inc.